We are excited to join other nuclear medicine leaders from around the globe at the Society of Nuclear Medicine and Molecular Imaging's Annual Meeting in Chicago.
Stop by Booth #1039 or schedule a meeting with us below.
We are currently producing lutetium-177 and shipping product from our clinical-scale facility in Janesville, Wisconsin, USA. Learn more about how we're scaling our production of n.c.a. Lu-177, and about our plans for other fusion-driven medical isotopes (Mo-99,
I-131, Tb-161).
Our n.c.a. Lu-177 is produced in accordance with Good Manufacturing Practice and meets or exceeds all U.S. and European pharmacopeia standards. We submitted a Drug Master File to the U.S. FDA in 2022. We are working to rapidly expand our production capabilities, including aiming to bring our large-scale facility, Cassiopeia, online in 2023.
We stand apart from other fusion companies because we have commercialized fusion today and we are scaling our technology. During each of our four phases, we’re perfecting core competencies needed for commercially viable fusion, producing useful products, building shareholder value, and reinvesting in future growth.
Join us and be part of the solution.
